Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies
NCT07345728Recruiting
- Start
- Jan 2026
- Primary completion
- Jun 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of BAFFR CAR-T in B cell lymphoma. Primary endpoint: Overall Survival at 24 months. Started Jan 2026; status: recruiting.
02
Drugs
BAFFR CAR-T
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07345728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07345728.